Longer follow-up results on CAR-T therapy and early results from a novel BiTE therapy for patients with acute lymphoblastic leukemia, early results on checkpoint inhibitors to treat Hodgkin’s lymphoma, and phase III results on brentuximab vedotin to prevent recurrence of Hodgkin’s lymphoma will head up our onsite coverage of the American Society of Hematology Annual Meeting, to be held Dec. 6-9 in San Francisco.
Engineered T cells for treating patients with acute lymphoblastic leukemia
Reports on targeted therapies at ASH 2014 will include the latest follow-up of children with refractory acute lymphoblastic leukemia (ALL) who were treated with T-cells engineered with a chimeric antigen receptor targeting CD19, and results from a phase II study of blinatumomab, a bispecific T cell engager (BiTE) antibody construct, in patients with minimal residual disease B-precursor ALL.
Checkpoint inhibitors for treating patients with Hodgkin’s lymphoma
The first analyses from two studies using PD-1 antibodies for the treatment of classical Hodgkin’s lymphoma will be reported. Investigators will report phase I results of nivolumab in 23 heavily pretreated patients with classical HL, and of pembrolizumab (MK-3475) in 15 patients with classical HL with previously failed treatment using brentuximab vedotin.
Preventing recurrence of Hodgkin’s lymphoma
Highly anticipated results from the Aethera trial, a phase III study of brentuximab vedotin in 327 patients at risk of progression following autologous stem cell transplant for Hodgkin’s lymphoma, will also be reported.
lnikolaides@frontlinemedcom.com
On Twitter@nikolaideslaura